Approved for use through DV31/2006. OMB 0651-0031
U.S. Patent and Trademask Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unities at contains a valid OMB control number.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10593245			
iling Date		2005-03-18			
irst Named Inventor LARS		EN, Finn			
Art Unit					
Examiner Name					
Mornov Docket Number		20747/340(ARDRW/P32846LIS)			

					U.S.	PATENTS			Remove		
Examiner Initial*	Examiner Cite No Patent Number Kind Code1 Issue		Issue E	Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1	4678661		1987-07	-07	GERGELY et	al.				
If you wis	h to a	i dd additional U.S. Patei	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	n Name of Patentee or Applicant of cited Document		Releva		Lines where ges or Relev	
	1	20020071864	A1	2002-06	i-13	KIM et al.					
If you wisi	h to a	dd additional U.S. Publi				information p		d button	Add		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	,	Kind Code ⁴	Publication	Name of Patente Applicant of cited Document	or v	ages,Co	umns,Lines evant or Relevant	T=
	1	0 232 877	EP		A2	1987-08-19	ZETACHRON, INC				С
	2	0 505 319	EP		B1	1995-02-15	GLATT GMBH				Г
	3	0 517 211	EP		A1	1992-12-09	TEIKOKU SEIYAKI KABUSHIKI KAISH				С

4	1 006 997	E₽	B1	2003-07-02	PIERRE FABRE MEDICAMENT	×
5	0 203 768	EP	B2	1993-05-26	WARNER-LAMBERT COMPANY	
6	0 205 336	EP	B1	1991-09-11	TEIJIN LIMITED	
7	0 415 326	EP	B1	1994-09-28	SS PHARMACEUTICAL CO., LTD.	
8	0 670 160	EΡ	B1	1999-07-14	GERGELY	
9	2 758 265	FR	A1	1998-07-17	PIERRE FABRE MEDICAMENT	×
10	98/31342	wo		1998-07-23	PIERRE FABRE MEDICAMENT	×
11	0 833 619	EP EP	B1	2000-12-27	PENTECH PHARMACEUTICALS, INC.	
12	1 017 371	EP	B1	2003-07-02	PENTECH PHARMACEUTICALS, INC.	
13	99/27905	wo		1999-06-10	DANBIOSYST UK LIMITED	
14	03/094885	wo	A1	2003-11-20	FERRING BV	

| Application Number | 10583245 | Fing Date | 2005.03-18 | Fing Date | 2005.03-18 | Fing Date | 2005.03-18 | Find Number | 2005.0

If you wiel	h th a	dd add	titional Foreign Patent Document citation information please click the Add but	ton A	dd		
ii jou ma		JU 440	NON-PATENT LITERATURE DOCUMENTS		nove		
Examiner Initials*	Cite No	(bool	de name of the author (in CAPITAL LETTERS), title of the article (when appr. k, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume sher, city and/or country where published.				Ts
	1						
If you wis	h to a	dd add	ditional non-patent literature document citation information please click the Ad	d button	Add		
			EXAMINER SIGNATURE				
Examiner	Signa	ture	Date Considered	Т			
			reference considered, whether or not citation is in conformance with MPEP 6 rmance and not considered. Include copy of this form with next communicati			rough a	

Take Kind Codes of USPTO Platent Documents at year, USPTO DOLY or MEPP 901.04. * Enter office and issued the document, by the lock-later code (WIPO Standard ST.3.) ** Explainate partial conserved, the inclusion to the year of the steps or the Steps or the Engineer reparts occurred the sentil number of the partent document, and included on the document by the appropriate symbols as included on the document under WIPO Standard ST.16 if possible. **Applicant is to place a check mark here if Engine Integrages Presidents in standards.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10593245		
Filing Date		2005-03-18		
First Named Inventor LARS		EN, Finn		
Art Unit				
Examiner Name				
Attornou Docket Number		20747/340(ARDRW/P32846LIS)		

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to make th	e appropriate selection(s):
---------------	----------	---------------------	-----------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(4)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

of the signature.							
	Signature	/Edwin V. Merkel/	Date (YYYY-MM-DD)	2007-07-20			
	Name/Print	Edwin V Merkel	Registration Number	40.087			

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. DIO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.